CD52抗体;CD52 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P13778(CD52 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

CD52 is a small, glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein (21–28 kDa) expressed abundantly on immune cells, including T and B lymphocytes, monocytes, macrophages, and eosinophils. Initially identified in the 1980s, its exact physiological role remains unclear, though it may modulate cell signaling and adhesion. CD52 became a therapeutic target due to its dense expression on malignant lymphocytes in chronic lymphocytic leukemia (CLL) and certain lymphomas.

The anti-CD52 antibody alemtuzumab (Campath-1H), a humanized monoclonal antibody, was developed in the 1990s. It binds CD52. triggering antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated lysis, depleting target cells. Approved in 2001 for CLL, alemtuzumab later gained attention for treating relapsing-remitting multiple sclerosis (MS) by resetting the immune system through transient lymphocyte depletion.

Despite efficacy, alemtuzumab’s use is limited by significant side effects, including increased infection risk and secondary autoimmune disorders (e.g., thyroid dysfunction). Research continues to explore CD52’s role in immune regulation, including its soluble form and interactions with innate immune cells. Recent studies also investigate repurposing CD52-targeting antibodies in transplantation and autoimmune diseases, balancing therapeutic benefits with immune modulation risks.